Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All iota‑carrageenan studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchIota-carrageenanIota-carragee.. (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Griffithsin and Carrageenan Combination Results in Antiviral Synergy against SARS-CoV-1 and 2 in a Pseudoviral Model

Alsaidi et al., Marine Drugs, doi:10.3390/md19080418
Jul 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
In Vitro and In Silico analysis showing SARS-CoV-2 antiviral activity of carageenan, and synergistic activity from the combination of carrageenan and griffithsin.
15 preclinical studies support the efficacy of iota-carrageenan for COVID-19:
Alsaidi et al., 26 Jul 2021, peer-reviewed, 12 authors.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
This PaperIota-carragee..All
Griffithsin and Carrageenan Combination Results in Antiviral Synergy against SARS-CoV-1 and 2 in a Pseudoviral Model
Sahar Alsaidi, Nadjet Cornejal, Oneil Mahoney, Claudia Melo, Neeharika Verma, Thierry Bonnaire, Theresa Chang, Barry R O’keefe, James Sailer, Thomas M Zydowsky, Natalia Teleshova, José A Fernández Romero
Marine Drugs, doi:10.3390/md19080418
Over 182 million confirmed cases of COVID-19 and more than 4 million deaths have been reported to date around the world. It is essential to identify broad-spectrum antiviral agents that may prevent or treat infections by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) but also by other coronaviruses that may jump the species barrier in the future. We evaluated the antiviral selectivity of griffithsin and sulfated and non-sulfated polysaccharides against SARS-CoV-1 and SARS-CoV-2 using a cytotoxicity assay and a cell-based pseudoviral model. The half-maximal cytotoxic concentration (CC 50 ) and half-maximal effective concentration (EC 50 ) were determined for each compound, using a dose-response-inhibition analysis on GraphPad Prism v9.0.2 software (San Diego, CA, USA). The therapeutic index (TI = CC 50 /EC 50 ) was calculated for each compound. The potential synergistic, additive, or antagonistic effect of different compound combinations was determined by CalcuSyn v1 software (Biosoft, Cambridge, UK), which estimated the combination index (CI) values. Iota and lambda carrageenan showed the most potent antiviral activity (EC 50 between 3.2 and 7.5 µg/mL). Carrageenan and griffithsin combinations exhibited synergistic activity (EC 50 between 0.2 and 3.8 µg/mL; combination index <1), including against recent SARS-CoV-2 mutations. The griffithsin and carrageenan combination is a promising candidate to prevent or treat infections by SARS-CoV-1 and SARS-CoV-2.
References
Buck, Thompson, Roberts, Muller, Lowy et al., Carrageenan is a potent inhibitor of papillomavirus infection, PLoS Pathog, doi:10.1371/journal.ppat.0020069
Derby, Lal, Aravantinou, Kizima, Barnable et al., Griffithsin carrageenan fast dissolving inserts prevent SHIV HSV-2 and HPV infections in vivo, Nat. Commun, doi:10.1038/s41467-018-06349-0
Fernandez-Romero, Abraham, Rodriguez, Kizima, Jean-Pierre et al., Zinc acetate/carrageenan gels exhibit potent activity in vivo against high-dose herpes simplex virus 2 vaginal and rectal challenge, Antimicrob. Agents Chemother, doi:10.1128/AAC.05461-11
Friedland, Hoesley, Plagianos, Hoskin, Zhang et al., First-in-Human Trial of MIV-150 and Zinc Acetate Coformulated in a Carrageenan Gel: Safety, Pharmacokinetics, Acceptability, Adherence, and Pharmacodynamics, JAIDS J. Acquir. Immune Defic. Syndr, doi:10.1097/QAI.0000000000001136
Guarner, Three Emerging Coronaviruses in Two Decades, Am. J. Clin. Pathol, doi:10.1093/ajcp/aqaa029
Hebar, Koller, Seifert, Chabicovsky, Bodenteich et al., Non-clinical safety evaluation of intranasal iota-carrageenan, PLoS ONE, doi:10.1371/journal.pone.0122911
Hoffmann, Kleine-Weber, Schroeder, Kruger, Herrler et al., SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor, Cell, doi:10.1016/j.cell.2020.02.052
Koenighofer, Lion, Bodenteich, Prieschl-Grassauer, Grassauer et al., Carrageenan nasal spray in virus confirmed common cold: Individual patient data analysis of two randomized controlled trials, Multidiscip. Respir. Med, doi:10.1186/2049-6958-9-57
Kwon, Oh, Kwon, Jin, Zhang et al., Sulfated polysaccharides effectively inhibit SARS-CoV-2 in vitro, Cell Discov, doi:10.1038/s41421-020-00192-8
Lee, Griffithsin, a Highly Potent Broad-Spectrum Antiviral Lectin from Red Algae: From Discovery to Clinical Application, Mar. Drugs, doi:10.3390/md17100567
Leibbrandt, Meier, Konig-Schuster, Weinmullner, Kalthoff et al., Iota-carrageenan is a potent inhibitor of influenza A virus infection, PLoS ONE, doi:10.1371/journal.pone.0014320
Leung, Shum, Leung, Lam, Wu, Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to, Eurosurveillance, doi:10.2807/1560-7917.ES.2020.26.1.2002106
Levendosky, Mizenina, Martinelli, Jean-Pierre, Kizima et al., Griffithsin and Carrageenan Combination To Target Herpes Simplex Virus 2 and Human Papillomavirus, Antimicrob. Agents Chemother, doi:10.1128/AAC.01816-15
Lusvarghi, Bewley, Griffithsin: An Antiviral Lectin with Outstanding Therapeutic Potential, Viruses, doi:10.3390/v8100296
Morokutti-Kurz, Froba, Graf, Grosse, Grassauer et al., Iota-carrageenan neutralizes SARS-CoV-2 and inhibits viral replication in vitro, PLoS ONE
Moulaei, Alexandre, Shenoy, Meyerson, Krumpe et al., Griffithsin tandemers: Flexible and potent lectin inhibitors of the human immunodeficiency virus, Retrovirology, doi:10.1186/s12977-014-0127-3
O'keefe, Giomarelli, Barnard, Shenoy, Chan et al., Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae, J. Virol, doi:10.1128/JVI.02322-09
O'keefe, Vojdani, Buffa, Shattock, Montefiori et al., Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component, Proc. Natl. Acad. Sci, doi:10.1073/pnas.0901506106
Parker, Shrotri, Kampmann, Keeping track of the SARS-CoV-2 vaccine pipeline, Nat. Rev. Immunol, doi:10.1038/s41577-020-00455-1
Plante, Liu, Liu, Xia, Johnson et al., Spike mutation D614G alters SARS-CoV-2 fitness, Nature, doi:10.1038/s41586-020-2895-3
Rodriguez, Kleinbeck, Mizenina, Kizima, Levendosky et al., In vitro and in vivo evaluation of two carrageenan-based formulations to prevent HPV acquisition, Antivir. Res, doi:10.1016/j.antiviral.2014.05.018
Schmidt, Weisblum, Muecksch, Hoffmann, Michailidis et al., Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses, J. Exp. Med, doi:10.1084/jem.20201181
Shikov, Flisyuk, Obluchinskaya, Pozharitskaya, Pharmacokinetics of Marine-Derived Drugs, Mar. Drugs, doi:10.3390/md18110557
Sun, Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit, AAPS J, doi:10.1208/s12248-020-00459-8
Tegally, Wilkinson, Giovanetti, Iranzadeh, Fonseca et al., Detection of a SARS-CoV-2 variant of concern in South Africa, Nature, doi:10.1038/s41586-021-03402-9
Who, Coronavirus Disease (COVID-19) Pandemic
{ 'DOI': '10.3390/md19080418', 'ISSN': ['1660-3397'], 'URL': 'http://dx.doi.org/10.3390/md19080418', 'abstract': '<jats:p>Over 182 million confirmed cases of COVID-19 and more than 4 million deaths have been ' 'reported to date around the world. It is essential to identify broad-spectrum antiviral ' 'agents that may prevent or treat infections by severe acute respiratory syndrome coronavirus ' '2 (SARS-CoV-2) but also by other coronaviruses that may jump the species barrier in the ' 'future. We evaluated the antiviral selectivity of griffithsin and sulfated and non-sulfated ' 'polysaccharides against SARS-CoV-1 and SARS-CoV-2 using a cytotoxicity assay and a cell-based ' 'pseudoviral model. The half-maximal cytotoxic concentration (CC50) and half-maximal effective ' 'concentration (EC50) were determined for each compound, using a dose-response-inhibition ' 'analysis on GraphPad Prism v9.0.2 software (San Diego, CA, USA). The therapeutic index (TI = ' 'CC50/EC50) was calculated for each compound. The potential synergistic, additive, or ' 'antagonistic effect of different compound combinations was determined by CalcuSyn v1 software ' '(Biosoft, Cambridge, UK), which estimated the combination index (CI) values. Iota and lambda ' 'carrageenan showed the most potent antiviral activity (EC50 between 3.2 and 7.5 µg/mL). ' 'Carrageenan and griffithsin combinations exhibited synergistic activity (EC50 between 0.2 and ' '3.8 µg/mL; combination index &lt;1), including against recent SARS-CoV-2 mutations. The ' 'griffithsin and carrageenan combination is a promising candidate to prevent or treat ' 'infections by SARS-CoV-1 and SARS-CoV-2.</jats:p>', 'alternative-id': ['md19080418'], 'author': [ {'affiliation': [], 'family': 'Alsaidi', 'given': 'Sahar', 'sequence': 'first'}, {'affiliation': [], 'family': 'Cornejal', 'given': 'Nadjet', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Mahoney', 'given': 'Oneil', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0003-2663-1196', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Melo', 'given': 'Claudia', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Verma', 'given': 'Neeharika', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Bonnaire', 'given': 'Thierry', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0003-0696-9755', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Chang', 'given': 'Theresa', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0003-0772-4856', 'affiliation': [], 'authenticated-orcid': False, 'family': 'O’Keefe', 'given': 'Barry R.', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Sailer', 'given': 'James', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Zydowsky', 'given': 'Thomas M.', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Teleshova', 'given': 'Natalia', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0002-2864-8293', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Romero', 'given': 'José A. Fernández', 'sequence': 'additional'}], 'container-title': 'Marine Drugs', 'container-title-short': 'Marine Drugs', 'content-domain': {'crossmark-restriction': False, 'domain': []}, 'created': {'date-parts': [[2021, 7, 27]], 'date-time': '2021-07-27T02:22:46Z', 'timestamp': 1627352566000}, 'deposited': { 'date-parts': [[2021, 7, 27]], 'date-time': '2021-07-27T16:51:26Z', 'timestamp': 1627404686000}, 'indexed': { 'date-parts': [[2023, 12, 18]], 'date-time': '2023-12-18T14:29:55Z', 'timestamp': 1702909795264}, 'is-referenced-by-count': 28, 'issue': '8', 'issued': {'date-parts': [[2021, 7, 26]]}, 'journal-issue': {'issue': '8', 'published-online': {'date-parts': [[2021, 8]]}}, 'language': 'en', 'license': [ { 'URL': 'https://creativecommons.org/licenses/by/4.0/', 'content-version': 'vor', 'delay-in-days': 0, 'start': { 'date-parts': [[2021, 7, 26]], 'date-time': '2021-07-26T00:00:00Z', 'timestamp': 1627257600000}}], 'link': [ { 'URL': 'https://www.mdpi.com/1660-3397/19/8/418/pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '1968', 'original-title': [], 'page': '418', 'prefix': '10.3390', 'published': {'date-parts': [[2021, 7, 26]]}, 'published-online': {'date-parts': [[2021, 7, 26]]}, 'publisher': 'MDPI AG', 'reference': [ { 'key': 'ref1', 'unstructured': 'Coronavirus Disease (COVID-19) Pandemic\n' 'https://www.who.int/emergencies/diseases/novel-coronavirus-2019'}, {'DOI': '10.1093/ajcp/aqaa029', 'doi-asserted-by': 'publisher', 'key': 'ref2'}, { 'DOI': '10.2807/1560-7917.ES.2020.26.1.2002106', 'doi-asserted-by': 'publisher', 'key': 'ref3'}, {'DOI': '10.1038/s41577-020-00455-1', 'doi-asserted-by': 'publisher', 'key': 'ref4'}, {'DOI': '10.1038/s41586-020-2895-3', 'doi-asserted-by': 'publisher', 'key': 'ref5'}, {'DOI': '10.1038/s41586-021-03402-9', 'doi-asserted-by': 'publisher', 'key': 'ref6'}, {'DOI': '10.1016/j.cell.2020.02.052', 'doi-asserted-by': 'publisher', 'key': 'ref7'}, {'DOI': '10.1128/AAC.01816-15', 'doi-asserted-by': 'publisher', 'key': 'ref8'}, {'DOI': '10.1128/JVI.02322-09', 'doi-asserted-by': 'publisher', 'key': 'ref9'}, {'DOI': '10.1038/s41421-020-00192-8', 'doi-asserted-by': 'publisher', 'key': 'ref10'}, { 'DOI': '10.1371/journal.pone.0237480', 'article-title': 'Iota-carrageenan neutralizes SARS-CoV-2 and inhibits viral replication ' 'in vitro', 'author': 'Morokutti-Kurz', 'doi-asserted-by': 'crossref', 'journal-title': 'PLoS ONE', 'key': 'ref11', 'volume': '16', 'year': '2021'}, {'DOI': '10.1186/s12977-014-0127-3', 'doi-asserted-by': 'publisher', 'key': 'ref12'}, {'DOI': '10.3390/md17100567', 'doi-asserted-by': 'publisher', 'key': 'ref13'}, {'DOI': '10.1073/pnas.0901506106', 'doi-asserted-by': 'publisher', 'key': 'ref14'}, {'DOI': '10.3390/v8100296', 'doi-asserted-by': 'publisher', 'key': 'ref15'}, {'DOI': '10.1371/journal.ppat.0020069', 'doi-asserted-by': 'publisher', 'key': 'ref16'}, {'DOI': '10.1016/j.antiviral.2014.05.018', 'doi-asserted-by': 'publisher', 'key': 'ref17'}, {'DOI': '10.1097/QAI.0000000000001136', 'doi-asserted-by': 'publisher', 'key': 'ref18'}, {'DOI': '10.1371/journal.pone.0122911', 'doi-asserted-by': 'publisher', 'key': 'ref19'}, { 'key': 'ref20', 'series-title': 'CFR—Code of Federal Regulations. Title 21: Food and Drugs. Electronic ' 'Code Federal Regulation', 'year': '2014'}, {'DOI': '10.1186/2049-6958-9-57', 'doi-asserted-by': 'publisher', 'key': 'ref21'}, {'DOI': '10.1371/journal.pone.0014320', 'doi-asserted-by': 'publisher', 'key': 'ref22'}, {'DOI': '10.3390/md18110557', 'doi-asserted-by': 'publisher', 'key': 'ref23'}, {'DOI': '10.1208/s12248-020-00459-8', 'doi-asserted-by': 'publisher', 'key': 'ref24'}, {'DOI': '10.1038/s41467-018-06349-0', 'doi-asserted-by': 'publisher', 'key': 'ref25'}, {'DOI': '10.1128/AAC.05461-11', 'doi-asserted-by': 'publisher', 'key': 'ref26'}, {'DOI': '10.1084/jem.20201181', 'doi-asserted-by': 'publisher', 'key': 'ref27'}], 'reference-count': 27, 'references-count': 27, 'relation': {}, 'resource': {'primary': {'URL': 'https://www.mdpi.com/1660-3397/19/8/418'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': [ 'Drug Discovery', 'Pharmacology, Toxicology and Pharmaceutics (miscellaneous)', 'Pharmaceutical Science'], 'subtitle': [], 'title': 'Griffithsin and Carrageenan Combination Results in Antiviral Synergy against SARS-CoV-1 and 2 in ' 'a Pseudoviral Model', 'type': 'journal-article', 'volume': '19'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit